Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (31)

1

Clinical review report : indication: multiple sclerosis, relapsing-remittingOfatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH common drug review

Final (with redactions)

2

Clinical and economic review report : indication: Crohn diseaseVedolizumab (ENTYVIO SC) Takeda Canada Inc

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH common drug review

Final (with redactions)

3

CADTH Canadian Drug Expert Committee recommendation : indication: for the treatment of adult patients with moderately to severely active Crohn diseaseVedolizumab (Entyvio -- Takeda Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version 1.0.

4

Pharmacoeconomic report : Hoffman-La Roche Ltd. : indication: bleeding prevention, hemophilia AEmicizumab (Hemlibra)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, February 2021

CADTH drug reimbursement review

Final.

5

Clinical review report : Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia AEmicizumab (Hemlibra)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, February 2021

CADTH drug reimbursement review

Final (with redactions)

6

Clinical review report : (Hoffmann-La Roche Limited) : indication neuromyelitis optica spectrum disorderSatralizumab (Enspryng)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, June 2021

CADTH common drug review

Version: Final (with redactions).

7

Clinical review report : (Sun Pharma Global FZE) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapyTildrakizumab (Ilumya)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2021

CADTH common drug review

Version: Final.

8

Prediction of response to biological treatment with monoclonal antibodies in severe asthma

enthalten in: Biochemical pharmacology | 2020

von Kroes, J. | Zielhuis, S. | van Roon, E. | +1

9

CADTH Canadian Drug Expert Committee recommendation : indication : adult patients with refractory generalized myasthenia gravisEculizumab (Soliris -- Alexion Pharma Canada Corp.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2020

CADTH common drug review

10

CADTH Canadian Drug Expert Committee recommendation : indication : the treatment of neuromyelitis optica spectrum disorder (NMOSD)Eculizumab (Soliris - Alexion Pharma Canada Corp.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 24, 2020

CADTH common drug review